# TMSB4X

Source: https://onco.cc/targets/tmsb4x/  
OnCo record `tmsb4x` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.

## Summary

Plays an important role in the organisation of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerisation. Potent inhibitor of bone marrow derived stem cell differentiation.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 6 cohorts (1 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: thymosin beta 4 X-linked; Thymosin beta-4; TB4X; TMSB4
- Tags: cancer-genes-wave
- Symbol: TMSB4X
- Class: tumor-suppressor
- Biology: Plays an important role in the organisation of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerisation. Potent inhibitor of bone marrow derived stem cell differentiation. Acts by inhibits the entry of haematopoietic pluripotent stem cells into the S-phase. Location: Cytoplasm, cytoskeleton (UniProt). Locus Xp22.2 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Diffuse large B-cell lymphoma: Open Targets association 0.53 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11881: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11881
- UniProt P62328: https://www.uniprot.org/uniprotkb/P62328/entry
- NCBI Gene 7114: https://www.ncbi.nlm.nih.gov/gene/7114
- Ensembl ENSG00000205542: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205542

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/tmsb4x.json